The effect of emphysema on readmission and survival among smokers with heart failure

Puja Kohli1*, Pedro V. Staziaki2*, Sumbal A. Janjua3, Daniel A. Addison2, Travis R. Hallett2, Orla Hennessy2, Richard A. P. Takx2, Michael T. Lu2, Florian J. Fintelmann3, Marc Semigran4, Robert S. Harris1, Bartolome R. Celli5, Udo Hoffmann2, Tomas G. Neilan2,4

1 Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2 Cardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 3 Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 4 Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 5 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham & Women’s Hospital, Boston, Massachusetts, United States of America

* These authors contributed equally to this work.

pkohli1@mgh.harvard.edu

Abstract

Heart Failure (HF) and chronic obstructive pulmonary disease (COPD) are morbid diseases that often coexist. In patients with coexisting disease, COPD is an independent risk factor for readmission and mortality. However, spirometry is often inaccurate in those with active heart failure. Therefore, we investigated the association between the presence of emphysema on computed tomography (CT) and readmission rates in smokers admitted with heart failure (HF). The cohort included a consecutive group of smokers discharged with HF from a tertiary center between January 1, 2014 and April 1, 2014 who also had a CT of the chest for dyspnea. The primary endpoint was any readmission for HF before April 1, 2016; secondary endpoints were 30-day readmission for HF, length of stay and all-cause mortality. Over the study period, there were 225 inpatient smokers with HF who had a concurrent chest CT (155 [69%] males, age 69 ± 11 years, ejection fraction [EF] 46 ± 18%, 107 [48%] LVEF of < 50%). Emphysema on CT was present in 103 (46%) and these were older, had a lower BMI, more pack-years, less diabetes and an increased afterload. During a follow-up of 2.1 years, there were 110 (49%) HF readmissions and 55 (24%) deaths. When separated by emphysema on CT, any readmission, 30-day readmission, length of stay and mortality were higher among HF patients with emphysema. In multivariable regression, emphysema by CT was associated with a two-fold higher (adjusted HR 2.11, 95% CI 1.41–3.15, p < 0.001) risk of readmission and a trend toward increased mortality (adjusted HR 1.70 95% CI 0.86–3.34, p = 0.12). In conclusion, emphysema on CT is a frequent finding in smokers hospitalized with HF and is associated with adverse outcomes in HF. This under recognized group of patients with both emphysema and heart failure may benefit from improved recognition and characterization of their co-morbid disease processes and optimization of therapies for their lung disease.
Introduction

Heart failure and chronic obstructive pulmonary disease (COPD) are both global epidemics that incur significant morbidity and mortality [1]. These systemic disorders often coexist with overlapping clinical symptoms and pathophysiologic processes [2]. Few have studied the prognostic implications of comorbid illness with HF and COPD, but these studies have shown that the presence of COPD is an independent predictor of death and HF hospitalization [2]. However, given the overlapping clinical signs and symptoms in this population and inaccurate spirometry measurements in patients with active heart failure [3,4], COPD is likely underdiagnosed.

While the care of patients with HF has improved dramatically [5], there is room for continued improvement [6]. Specifically, readmission after a HF hospitalization is still high [7]. For example, data have shown that within 30 to 60 days of discharge 30% of patients with HF will be re-hospitalized [8]. Reducing heart failure hospital readmissions is paramount for improved patient care and health care costs.

Emphysema is pathological destruction of alveoli leading to lung hyperinflation on chest CT, and is seen in 50% of patients with chronic obstructive pulmonary disease (COPD) [9] and in an estimated 44% of asymptomatic smokers [10]. Emphysema can be diagnosed using either pulmonary function testing (PFTs) or computed tomography (CT). However, data suggest that emphysema by CT may be a more sensitive measure of lung disease [11], especially in HF, may be a better predictor of adverse outcomes [12,13] and is associated with a lower cardiac output [14–16].

Despite the plausibility [17–23], there are no data that either test the effect of emphysema by CT on adverse outcomes among patients with complex HF or provide potential mechanistic insight in this population. In this study we aimed to add to this limited data and hypothesized that emphysema by CT is associated with an increase in hospital readmission and mortality among patients with complex HF.

Methods

This was a historical-cohort single-center study. This investigation conforms with the principles outlined in the Declaration of Helsinki and the research protocol was approved by the Partners Human Research Committee (PHRC), the Institutional Review Board (IRB) of Partners Healthcare, which waived the need for informed consent. The cohort was derived from the Partners HealthCare System Research Patient Data Registry (RPDR), a clinical care database of all inpatient and outpatient encounters from Massachusetts General Hospital. We queried RPDR for all patients with a primary discharge diagnosis of HF from January 1st to April 1st 2014. The cohort was then restricted to active or prior smokers and those who had a contemporary CT scan of the chest (within 2 years of HF discharge) performed for dyspnea. A discharge diagnosis of HF was adjudicated by investigators blinded to all other variables using the ACC/AHA definition of HF [24]. In total, three independent blinded groups performed each of the key components: clinical data collection, emphysema by CT, and event adjudication. The presence of emphysema was assessed using a CT scan of the chest by a board-certified pulmonologist blinded to all other data using validated criteria from the National Emphysema Treatment Trial [25]. In brief, using inspiratory CT scans, each lung was divided into three apical-to-basal zones, and each zone was evaluated visually. Emphysema was diagnosed by CT if at least one of the zones showed emphysematous lucencies in greater than 5% of the lung zone (grade 1).

The primary endpoint was the first readmission for HF after the index hospitalization for HF. The occurrence of a HF admission was defined based on ACC/AHA guidelines [24]. The
principal secondary end-point was all-cause mortality determined by electronic medical record. Two additional secondary end-points were pre-specified: 30-day readmission for HF and length of stay for the first readmission with HF.

Covariates were recorded at the time of the index hospitalization. In brief, cardiovascular risk factors collected included smoking history, hypertension, dyslipidemia, diabetes mellitus, presence of coronary artery disease, sleep apnea, body mass index (BMI), stroke or cerebrovascular accident and atrial fibrillation. Sleep apnea was defined based on sleep study criteria recommended by the American Academy of Sleep Medicine [26]. Stroke or cerebrovascular accident were defined as documented history of ischemic stroke, silent central nervous system (CNS) infarction, intracerebral hemorrhage, silent intracerebral hemorrhage, subarachnoid hemorrhage, central venous thrombosis, evidence of CNS infarction on imaging or pathology, or any episode of acute neurological dysfunction presumed to be caused by ischemia or hemorrhage, persisting ≥24 hours or until death [27]. Cardiovascular medications and ECG and echocardiogram data were also recorded. ECG parameters included presence of sinus rhythm, PR interval (msec), QRS width (msec) and the QTc (msec) interval. Echocardiographic parameters included the left atrial dimension (LA, mm), pulmonary artery systolic pressure (PASP, mmHg), posterior wall thickness in systole and diastole (PWT, mm), left ventricular ejection fraction (LVEF, %) and end-systolic wall stress as a measure of cardiac afterload. End-systolic wall stress was calculated based on American Society of Echocardiography recommendations [28]. Pulmonary specific factors included pulmonary function tests and lung medications.

Baseline characteristics, available for all participants, grouped by the presence or absence of emphysema, are presented as frequency (percentage) for categorical data and mean ± standard deviation or median (interquartile ranges [IQR]) for continuous data unless otherwise stated. Continuous data were compared with the use of unpaired Student t tests or Wilcoxon rank-sum tests when appropriate. Categorical data were compared using the chi-square or the Fisher exact test. Univariable and multivariable Cox regression analysis was performed. The hazard ratio for the prediction of events was calculated for first readmission, 30-day readmission, and for mortality rates using Cox proportional hazard models. In the multivariate analysis, we used two Cox regression models. In the first model, we included the predictors of readmission that had a p value < 0.1 on the univariate analysis. The second multivariable model was based on known predictors of HF hospitalization and emphysema and included age [29–32], gender [33], diabetes [32,34], hypertension [35], CAD [35], obstructive sleep apnea, chronic kidney disease [36–39], ejection fraction and sodium [40]. The proportional-hazards assumption was met in all models, and all models fit the data well. Event curves were determined according to the Kaplan-Meier method, and comparisons of cumulative event rates were performed by the log-rank test. Intervals were defined from date of index discharge. The end of the observation period included the earlier of two possible termination points: death or last encounter prior to April 1st 2016. All analyses were performed using R (Version 3.2.2, The R Foundation for Statistical Computing Platform) and a two-sided p value of < 0.05 was considered statistically significant.

Results

The RPDR query yielded 520 patients with a primary adjudicated discharge diagnosis of HF from January 1st to April 1st 2014 (Fig 1). Overall, there were 314 current or past smokers among the 520 subjects discharged from this facility over a 3-month period with HF. Subsequently, patients without a contemporary CT scan (91 subjects) were excluded leaving a final study cohort of 225 smokers with adjudicated HF discharged from an academic center over a 3-month period with a recent chest CT. Complete details of the cohort are presented in
Patients with a primary discharge diagnosis of HF from January 1st to April 1st, 2014

520

Excluded: 206 – no history smoking

314

Excluded: 89 – no chest CT

Eligible patients:
- Prior discharge diagnosis of HF
- With chest CT
- With history of smoking

225

Prior COPD
101

No prior COPD
124

Fig 1. Flow diagram. Flow diagram describing the inclusion and exclusion criteria for the study population.

https://doi.org/10.1371/journal.pone.0201376.g001
Table 1. In brief, the mean age was 69 ± 11 years, there were 155 (69%) males, 167 (74%) had hypertension, 111 (49%) had diabetes and 123 (55%) had CAD and the average number of pack-years was 39. In total, 101 (45%) had a clinician diagnosis of COPD and the average predicted FEV1 among that population was 63% ± 20. The average LVEF was 47% ± 18 and 107 (48%) had an LVEF of < 50%. The cohort was separated by the presence or absence of emphysema on CT (Table 1). Overall, 103 (46%) patients had emphysema on CT (Table 1). Patients with emphysema on CT were older, had a lower BMI, a higher number of pack-years, more likely to have clinician diagnosed COPD, less likely to have diabetes and had a markedly increased afterload (end-systolic wall stress). Other co-morbidities, use of standard HF medications and LVEF were similar between groups. There were 50 patients (48%) in the emphysema group with an LVEF of < 50%. Among those with PFTs (n = 80), there was a significant difference in the forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio between those with and without emphysema by CT (FEV1/FVC 63 vs 74, p = 0.0004). However there was no difference between the FEV1 or the predicted residual volume.

In Table 3 we compared covariates between those readmitted with HF and those not readmitted with HF within the duration of the study. As compared to those not re-admitted with HF, those readmitted had decreased usage of inhaled anti-muscarinics. All other prior medical conditions and medications were similar between the two groups.

Follow-up was available for all subjects and the median follow-up period was 1.3 (IQR 1.1–1.4) year. During follow-up, 55 patients died (24% of cohort). There were 35 (64%) deaths among the 103 patients with emphysema as compared to 20 (36%) deaths among the 122 patients without (p = 0.002). The median time to death was 448 days in the full cohort, 440 days in patients with emphysema on CT vs. 453 days in the patients without emphysema on CT (Table 4). Patients with emphysema on CT had a higher likelihood of death regardless of whether they had co-existent heart failure with preserved ejection fraction (OR 3.4, p = 0.01) or reduced ejection fraction (OR = 2.75, p = 0.04). (Table 5)

In this cohort, there were 110 subjects (49%) readmitted with HF. The median time to first readmission with HF after the index hospitalization was 224 days. Overall, 64 of 103 patients (58%) with emphysema were readmitted with HF as compared to 46 of 122 patients (42%; p < 0.001). The median time to readmission for decompensated HF was 162 days in the patients with emphysema vs. 327 days in the patients without emphysema. (Table 4)

Overall, 36 (16%) patients were readmitted in 30 days or less. There were 25 (24%) 30-day readmissions among the 103 patients with emphysema as compared to 11 (9%) among the 122 patients without (p = 0.002). The median length of stay once readmitted with HF was longer among patients with emphysema than those without (7 days, IQR 5–8 vs. 5 days, IQR 3–8, p = 0.004). (Table 4)

In the univariable model, only emphysema on CT was associated with readmissions (Table 6, HR 2.07, 95% CI 1.42–3.04, p < 0.001). In the multivariable model adjusting for factors known to be predictive of readmission and mortality (Model 2), the presence of emphysema on CT was independently associated with an increased risk of readmission (Table 6, HR 2.11, 95% CI 1.41–3.15, p < 0.001).

Emphysema on CT was associated with mortality in the univariate model (Table 7, HR 2.11, 95% CI 1.21–3.68, p < 0.001), along with age, sodium and PASP. In a multivariable model incorporating univariate predictors of mortality (i.e., age, sodium, and PASP), the presence of emphysema was found to be a trend toward increased mortality (Table 7, adjusted HR 1.70, 95% CI 0.86–3.34, p = 0.12). In a second multi-variable model, adjusting for factors
| Variables                      | All patients n = 225 | Emphysema, no n = 122 | Emphysema, yes n = 103 | p Value |
|--------------------------------|----------------------|------------------------|------------------------|---------|
| Age (years)                    | 69 ± 11              | 68 ± 11                | 71 ± 10                | 0.02    |
| Male                           | 155 (69%)            | 88 (72%)               | 67 (65%)               | 0.25    |
| BMI (kg/m²)                    | 30 ± 8.2             | 32 ± 8.9               | 28 ± 6.9               | 0.01    |
| Pack-years                     | 39 ± 28              | 32 ± 23                | 48 ± 32                | < 0.001 |
| Prior medical conditions       |                      |                        |                        |         |
| Hypertension                   | 167 (74%)            | 95 (78%)               | 72 (70%)               | 0.17    |
| Diabetes mellitus              | 111 (49%)            | 71 (58%)               | 40 (39%)               | 0.004   |
| Dyslipidemia                   | 121 (54%)            | 66 (54%)               | 55 (53%)               | 0.92    |
| Chronic kidney disease         | 61 (27%)             | 39 (32%)               | 22 (21%)               | 0.07    |
| Obstructive sleep apnea        | 36 (16%)             | 19 (16%)               | 17 (16%)               | 0.84    |
| Valvular disease               | 50 (22%)             | 22 (18%)               | 28 (27%)               | 0.10    |
| CAD                            | 123 (55%)            | 66 (54%)               | 57 (55%)               | 0.85    |
| PAD                            | 26 (11%)             | 12 (9.8%)              | 14 (14%)               | 0.38    |
| Stroke                         | 29 (13%)             | 19 (15%)               | 10 (9.7%)              | 0.19    |
| Atrial fibrillation            | 105 (47%)            | 61 (50%)               | 44 (43%)               | 0.27    |
| Chronic lung diseases          |                      |                        |                        |         |
| COPD                           | 104 (45%)            | 38 (31%)               | 63 (61%)               | < 0.001 |
| Asthma                         | 15 (6.6%)            | 10 (8.1%)              | 5 (4.8%)               | 0.32    |
| Pulmonary medications at discharge |                  |                        |                        |         |
| Inhaled steroids               | 29 (13%)             | 13 (11%)               | 16 (15%)               | 0.28    |
| Inhaled beta-agonists          | 75 (33%)             | 35 (29%)               | 40 (39%)               | 0.11    |
| Inhaled LA antimuscarinic       | 54 (24%)             | 18 (15%)               | 36 (35%)               | < 0.001 |
| Oral corticosteroids           | 19 (8.4%)            | 7 (6.7%)               | 12 (12%)               | 0.11    |
| Other medications at discharge |                      |                        |                        |         |
| Aspirin                        | 177 (79%)            | 95 (78%)               | 82 (80%)               | 0.75    |
| ACEI/ARB                       | 178 (79%)            | 91 (74%)               | 87 (84%)               | 0.07    |
| Beta-blocker                   | 203 (90%)            | 113 (93%)              | 90 (87%)               | 0.19    |
| Calcium channel blocker        | 42 (19%)             | 27 (22%)               | 15 (15%)               | 0.15    |
| Statin                         | 172 (76%)            | 93 (76%)               | 79 (77%)               | 0.93    |
| Aldosterone antagonist         | 50 (22%)             | 32 (26%)               | 18 (17%)               | 0.11    |
| Diuretics                      | 207 (92%)            | 112 (92%)              | 95 (92%)               | 0.91    |
| Nitrates                       | 41 (18%)             | 24 (20%)               | 17 (16%)               | 0.54    |
| Digoxin                        | 28 (12%)             | 11 (9)                 | 17 (16)                | 0.09    |
| Coumadin                       | 88 (39%)             | 47 (38%)               | 41 (40%)               | 0.84    |
| Heart rate (bpm)               | 81 ± 17              | 82 ± 18                | 81 ± 17                | 0.83    |
| Systolic blood pressure (mm Hg)| 132 ± 27             | 132 ± 27               | 131 ± 28               | 0.75    |
| Diastolic blood pressure (mm Hg)| 72 ± 13              | 72 ± 14                | 71 ± 13                | 0.68    |
| Laboratory values              |                      |                        |                        |         |
| Sodium                         | 137 ± 4.1            | 137 ± 4.3              | 137 ± 3.8              | 0.57    |
| Creatinine                     | 1.3 (1.0–1.8)        | 1.3 (1.0–2.0)          | 1.3 (1.0–1.8)          | 0.63    |
| Blood urea nitrogen            | 31 (19–45)           | 32 (19–47)             | 28 (17–41)             | 0.11    |
| ECG                            |                      |                        |                        |         |
| Non-sinus rhythm               | 81 (36%)             | 45 (39%)               | 36 (38%)               | 0.94    |
| P-R interval (msec)            | 174 ± 34             | 177 ± 35               | 170 ± 33               | 0.23    |
| QRS duration (msec)            | 119 ± 35             | 120 ± 35               | 117 ± 35               | 0.41    |
| QTc (msec)                     | 474 ± 50             | 476 ± 46               | 472 ± 54               | 0.52    |

(Continued)
known to be predictive of mortality, the presence of emphysema on CT was independently associated with mortality (Table 7, adjusted HR 2.10, 95% CI 1.16–3.76, p = 0.01). Kaplan-Meier curves generated for readmissions and event-free survival among patients with and without emphysema are presented (Fig 2).

### Discussion

In this study, we determined the associations between emphysema on chest CT and baseline variables among a consecutive group of smokers who were hospitalized with HF and subsequently tested the association between the presence of emphysema on chest CT and outcomes among these patients. The following were the principal findings: 1. Emphysema by CT is highly prevalent among prior or active smokers admitted with HF; 2. 40 (39%) prior or active smokers with HF who had emphysema on CT did not have a clinical diagnosis of COPD; 3. The presence of emphysema is associated with a markedly increased afterload; 4. The presence of emphysema among patients with HF provided prognostic information, with emphysema being associated with increased readmission for HF, a longer length of stay, and increased mortality.

These data on the high rate of adverse events among prior or active smokers with HF are complementary and additive to prior data. For example, in the observational Worcester Heart Failure Study, containing 9,748 patients hospitalized with HF, patients with clinical COPD, the combination of emphysema and bronchitis, had a significantly higher mortality at 1 year [22].
Table 3. Patient characteristics by HF readmission status.

| Variables                              | All patients | No readmission | Readmission | p Value |
|----------------------------------------|--------------|----------------|-------------|---------|
|                                        | n = 225      | n = 110        | n = 115     |         |
| Age                                    | 69 ± 11      | 69 ± 11        | 69 ± 11     | 0.73    |
| Male                                   | 155 (69)     | 74 (64)        | 81 (74)     | 0.13    |
| BMI                                    | 30 ± 8.2     | 30 ± 8.6       | 31 ± 7.8    | 0.44    |
| Pack-years                             | 39 ± 28      | 37 ± 27        | 41 ± 30     | 0.27    |
| Prior medical conditions               |              |                |             |         |
| Hypertension                           | 167 (74)     | 84 (73)        | 83 (75)     | 0.68    |
| Diabetes mellitus                      | 111 (49)     | 61 (53)        | 50 (45)     | 0.25    |
| Dyslipidemia                           | 121 (54)     | 59 (51)        | 62 (56)     | 0.45    |
| Chronic kidney disease                 | 61 (27)      | 32 (29)        | 29 (26)     | 0.80    |
| Obstructive sleep apnea                | 36 (16)      | 16 (14)        | 20 (18)     | 0.38    |
| Valvular disease                       | 50 (22)      | 24 (21)        | 26 (24)     | 0.62    |
| CAD                                    | 123 (55)     | 59 (51)        | 64 (58)     | 0.30    |
| PAD                                    | 26 (11)      | 12 (10)        | 14 (13)     | 0.59    |
| Stroke                                 | 29 (13)      | 17 (15)        | 12 (11)     | 0.39    |
| Atrial fibrillation                    | 105 (47)     | 58 (50)        | 47 (43)     | 0.25    |
| Chronic lung diseases                  |              |                |             |         |
| COPD                                   | 104 (45)     | 46 (40)        | 55 (50)     | 0.13    |
| Asthma                                 | 15 (6.6)     | 10 (8.7)       | 5 (4.5)     | 0.21    |
| Pulmonary function tests               |              |                |             |         |
| FEV1 (%)                               | 63 ± 20      | 64 ± 20        | 61 ± 19     | 0.52    |
| FVC (%)                                | 57 ± 33      | 67 ± 28        | 49 ± 34     | 0.02    |
| RV (%)                                 | 109 ± 40     | 109 ± 59       | 109 ± 29    | 0.98    |
| DLCO (%)                               | 52 ± 21      | 47 ± 20        | 55 ± 22     | 0.13    |
| Pulmonary medications at discharge     |              |                |             |         |
| Inhaled steroids                       | 29 (13)      | 18 (16)        | 11 (10)     | 0.21    |
| Inhaled beta-agonists                  | 75 (33)      | 43 (37)        | 32 (29)     | 0.19    |
| Inhaled LA antimuscarinic              | 54 (24)      | 34 (30)        | 20 (18)     | < 0.05  |
| Oral corticosteroids                   | 19 (8.4)     | 12 (10)        | 7 (6.4)     | 0.27    |
| Other medications at discharge         |              |                |             |         |
| Aspirin                                | 177 (79)     | 91 (79)        | 86 (78)     | 0.86    |
| ACEI/ARB                               | 178 (79)     | 92 (80)        | 86 (78)     | 0.74    |
| Beta-blocker                           | 203 (90)     | 106 (92)       | 97 (88)     | 0.31    |
| Calcium channel blocker                | 42 (19)      | 18 (16)        | 24 (22)     | 0.23    |
| Statin                                 | 172 (76)     | 88 (76)        | 84 (76)     | 0.98    |
| Aldosterone antagonist                 | 50 (22)      | 29 (21)        | 21 (19)     | 0.27    |
| Diuretics                              | 207 (92)     | 104 (90)       | 103 (94)    | 0.38    |
| Nitrates                               | 41 (18)      | 19 (16)        | 22 (20)     | 0.50    |
| Digoxin                                | 28 (12)      | 13 (11)        | 15 (14)     | 0.60    |
| Coumadin                               | 88 (39)      | 45 (39)        | 43 (39)     | 0.99    |
| Heart rate (bpm)                       | 81 ± 17      | 81 ± 17        | 82 ± 18     | 0.64    |
| Systolic blood pressure (mm Hg)        | 132 ± 27     | 129 ± 26       | 134 ± 28    | 0.23    |
| Diastolic blood pressure (mm Hg)       | 72 ± 13      | 71 ± 14        | 73 ± 13     | 0.21    |
| Laboratory values                      |              |                |             |         |
| Sodium                                 | 137 ± 4.1    | 137 ± 4.0      | 136 ± 4.0   | 0.92    |
| Creatinine                             | 1.3 (1.0–1.8)| 1.3 (1.0–1.8)  | 1.2 (0.9–1.8)| 0.22    |
| Blood urea nitrogen                    | 31 (19–45)   | 29 (19–41)     | 31 (18–48)  | 0.50    |

(Continued)
In the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) study, subjects with an LVEF of < 35% were randomized to usual care with or without aerobic exercise training; 249 patients had a clinical diagnosis of COPD. During follow-up, COPD was associated with a 1.5 fold increased risk of the combined end-point of CV mortality and HF hospitalization [41]. In our contemporary study where most individuals were on standard HF therapies, we found that the risk of readmission and mortality was high among this population. Specifically, over the duration of this study, approximately 50% of patients were readmitted, the 30-day readmission rate was 36 (16%) and 24% of patients died. These data suggest that additional awareness, biomarkers, and additional therapies may be of use to help both stratify and treat this vulnerable population.

A major diagnostic and therapeutic challenge in this group of patients with comorbid disease is teasing out whether their symptoms are due to pulmonary edema from heart failure or an acute exacerbation of obstructive airways disease. In our study, researchers blinded to all other variables used well established criteria to confirm the diagnosis of heart failure, including the use of echocardiographic features of left ventricular dysfunction. However, since these two

| Variables | All patients | No readmission | Readmission | p Value |
|-----------|-------------|----------------|-------------|---------|
| ECG       |             | n = 225        | n = 110     | n = 115 |         |
| Non-sinus rhythm | 81 (36) | 37 (34) | 44 (43) | 0.19 |
| P-R interval (msec) | 174 ± 34 | 176 ± 37 | 172 ± 31 | 0.46 |
| QRS duration (msec) | 119 ± 35 | 117 ± 34 | 120 ± 36 | 0.53 |
| QTc (msec) | 474 ± 50 | 472 ± 46 | 477 ± 54 | 0.49 |
| Cardiac ultrasound | | | | |
| LA dimension (mm) | 45 ± 7.0 | 45 ± 7.6 | 46 ± 6.4 | 0.12 |
| LVIDd (mm) | 52 ± 9 | 51 ± 9 | 53 ± 9 | 0.20 |
| LVIDs (mm) | 40 ± 11 | 40 ± 11 | 40 ± 11 | 0.91 |
| PWT (mm) | 11 ± 2.2 | 11 ± 2.0 | 11 ± 2.4 | 0.25 |
| SWT or IVS (mm) | 12 ± 2.6 | 12 ± 2.3 | 12 ± 2.9 | 0.80 |
| LVEF (%) | 46 ± 18 | 47 ± 17 | 47 ± 19 | 0.99 |
| PASP (mm Hg) | 46 ± 14 | 45 ± 15 | 46 ± 13 | 0.69 |
| ESWS | 89 ± 41 | 87 ± 41 | 90 ± 41 | 0.56 |

BMI = body mass index, CAD = coronary artery disease, PAD = peripheral arterial disease, COPD = chronic obstructive pulmonary disease, ILD = interstitial lung disease, LA = long-acting, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, NOAC = novel oral anticoagulants, ECG = electrocardiogram, LA = left atrium, PWT = posterior wall thickness, SWT = septal wall thickness, LVEF = left ventricular ejection fraction, PASP = pulmonary artery systolic pressure, ESWS = end-systolic wall stress

https://doi.org/10.1371/journal.pone.0201376.t003

| Variables | All patients | Emphysema, no | Emphysema, yes | p value |
|-----------|-------------|---------------|----------------|---------|
| Follow-up time | 466 (414–529) | 469 (418–525) | 464 (376–510) | 0.64 |
| Death | 55 (24) | 20 (36) | 35 (64) | < 0.001 |
| Time to death | 448 (268–507) | 453 (343–515) | 440 (249–500) | 0.38 |
| Any readmission | 110 (49) | 46 (42) | 64 (38) | < 0.001 |
| Time to readmission | 224 (59–451) | 327 (69–477) | 162 (31–323) | 0.003 |
| 30-day readmission | 36 (16) | 11 (9) | 25 (24) | 0.002 |

https://doi.org/10.1371/journal.pone.0201376.t004
diseases present with similar symptoms and often similar acute cardiopulmonary dysfunction, misclassification of the process considered to be the precipitant factor for hospitalization is always a possibility. Our current diagnostic tools including echocardiography [42,43], N-terminal pro-BNP [44] and pulmonary function testing [3] have variable accuracy in diagnosing exacerbations of HF and/or COPD in patients with comorbid illness. All of these tools require more robust studies to determine the diagnostic accuracy and utility in the complex HF patient population.

Computerized tomography is a sensitive and specific method for the diagnosis of emphysema; however, prior to this study, there was no prognostic information on the effect of emphysema by CT on outcomes specific to patients with HF. In the majority of studies, COPD is diagnosed using PFTs. However, the use of PFTs among patients with HF is limited. For example, in a study of 214 patients with valve disease and HF who never smoked, PFTs incorrectly diagnosed COPD in almost 45% of patients [45]. Additionally, in a study among non-smokers with HF, serial PFTs incorrectly diagnosed COPD in over 50% despite treatment and resolution of decomposition [4]. We found emphysema was present in almost 50% of smokers with HF and 39% without known COPD. We also found that the presence of emphysema by

| Table 5. Outcomes by cardiac function. |
|---------------------------------------|
|                                        |
| **HF with Preserved EF > 50%**         |
| All patients                          |
| n = 115                               |
| Emphysema, no                         |
| n = 64                                |
| Emphysema, yes                        |
| n = 51                                |
| Variables                              |
|                                       |
| Death                                 |
| 27 (23)                               |
| 9 (7)                                 |
| 18 (35)                               |
| p value                               |
| < 0.01                                |
| Readmission                           |
| 60 (52)                               |
| 23 (35)                               |
| 37 (73)                               |
| 0.001                                 |
| 30-day readmission                    |
| 25 (22)                               |
| 8 (12)                                |
| 17 (33)                               |
| < 0.001                               |
| **HF with Reduced EF < 50%**          |
| All patients                          |
| n = 110                               |
| Emphysema, no                         |
| n = 57                                |
| Emphysema, yes                        |
| n = 53                                |
| Variables                              |
|                                       |
| Death                                 |
| 27 (25)                               |
| 9 (16)                                |
| 28 (53)                               |
| 0.04                                 |
| Readmission                           |
| 53 (48)                               |
| 24 (42)                               |
| 29 (55)                               |
| 0.25                                 |
| 30-day readmission                    |
| 14 (13)                               |
| 5 (9)                                 |
| 9 (17)                                |
| 0.25                                 |

HF = heart failure, EF = ejection fraction

https://doi.org/10.1371/journal.pone.0201376.t005

| Table 6. Cox proportional hazards models for time to readmission. |
|---------------------------------------------------------------|
|                                                             |
| **Univariate analysis**                                      |
| HR (95% CI)                        p Value      | HR (95% CI)                        p Value      |
|-----------------------------------|-------------|-----------------------------------|-------------|
| Emphysema                         | 2.07 (1.42–3.04) | < 0.001                           | 2.11 (1.41–3.15) | < 0.001 |
| Age                               | 1.01 (0.99–1.02) | 0.44                              | 1.00 (0.98–1.02) | 0.98 |
| Sex                               | 1.26 (0.82–1.92) | 0.29                              | 1.35 (0.86–2.11) | 0.19 |
| Hypertension                      | 1.02 (0.66–1.58) | 0.82                              | 1.06 (0.68–1.67) | 0.78 |
| Diabetes mellitus                 | 0.82 (0.57–1.20) | 0.31                              | 0.93 (0.63–1.39) | 0.73 |
| Chronic kidney disease            | 0.96 (0.63–1.48) | 0.88                              | 0.96 (0.62–1.49) | 0.85 |
| Obstructive sleep apnea           | 1.27 (0.79–2.08) | 0.32                              | 1.31 (0.79–2.18) | 0.30 |
| CAD                               | 1.35 (0.92–1.97) | 0.12                              | 1.36 (0.90–2.05) | 0.15 |
| Sodium                            | 0.98 (0.93–1.02) | 0.30                              | 0.97 (0.92–1.02) | 0.29 |
| LVEF                              | 1.00 (0.99–1.01) | 0.97                              | 1.00 (0.99–1.02) | 0.36 |

HR = hazard ratio, CAD = coronary artery disease, LVEF = left ventricular ejection fraction, PASP = pulmonary artery systolic pressure

https://doi.org/10.1371/journal.pone.0201376.t006
CT was associated with both HF readmission and length of stay for HF hospitalization. Based on our findings, the presence of emphysema by CT predicted adverse outcomes in complex HF.

The mechanism by which emphysema on CT is associated with increased morbidity and mortality among patients with HF is not completely understood. In broad populations without known HF, emphysema is associated with several pathophysiological changes that are likely

| Table 7. Cox proportional hazards models for time to mortality. |
|---------------------------------------------------------------|
| **Univariate analysis** | **Multivariate analysis** |
| **Model 1** | **Model 2** | **Model 1** | **Model 2** | **Model 1** | **Model 2** |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Emphysema       | 2.11 (1.21–3.68) | 0.008           | 1.70 (0.86–3.34) | 0.12           | 2.10 (1.16–3.76) | 0.01           |
| Age             | 1.05 (1.02–1.08) | 0.002           | 1.04 (1.00–1.08) | 0.05           | 1.05 (1.02–1.08) | 0.001          |
| Sex             | 1.00 (0.56–1.77) | 0.99            | -               | -              | 1.06 (0.56–2.00) | 0.86           |
| Hypertension    | 0.89 (0.49–1.61) | 0.70            | -               | -              | 0.89 (0.46–1.73) | 0.73           |
| Diabetes mellitus | 1.14 (0.66–1.94) | 0.64            | -               | -              | 1.17 (0.67–2.06) | 0.57           |
| Chronic kidney disease | 1.38 (0.78–2.43) | 0.26            | -               | -              | 1.79 (0.97–3.28) | 0.06           |
| Obstructive sleep apnea | 1.31 (0.67–2.53) | 0.43            | -               | -              | 1.20 (0.60–2.40) | 0.60           |
| CAD             | 1.24 (0.72–2.14) | 0.43            | -               | -              | 1.02 (0.57–1.83) | 0.94           |
| Sodium          | 0.93 (0.87–0.98) | 0.01            | 0.87 (0.80–0.95) | 0.002          | 0.92 (0.86–0.98) | 0.01           |
| LVEF            | 1.00 (0.98–1.01) | 0.65            | -               | -              | 0.99 (0.98–1.01) | 0.57           |
| PASP            | 1.03 (1.01–1.05) | 0.006           | 1.03 (1.00–1.05) | 0.007          | -               | -              |

HR = hazard ratio, CAD = coronary artery disease, LVEF = left ventricular ejection fraction, PASP = pulmonary artery systolic pressure

CT was associated with both HF readmission and length of stay for HF hospitalization. Based on our findings, the presence of emphysema by CT predicted adverse outcomes in complex HF.

The mechanism by which emphysema on CT is associated with increased morbidity and mortality among patients with HF is not completely understood. In broad populations without known HF, emphysema is associated with several pathophysiological changes that are likely
detrimental among patients with HF. Specifically, emphysema is associated with an increased afterload, greater LV mass [14], higher pulmonary artery pressures and a lower cardiac output with a similar LVEF [15]. Relatively few studies have been designed to explore the possible pathophysiologic mechanisms underlying poor cardiovascular outcomes in this complex population living with COPD and HF. A study by Alter et al [46] found that in a cohort of patients with comorbid COPD and HF, increased LV wall stress by cardiac magnetic resonance imaging correlated with increasing severity of airflow obstruction as measured by reduced FEV1 and decreased FEV1/FVC ratio. This group and others postulate that the negative pleural pressure caused by inspiring against increased airways resistance is transmitted to the heart causing increased transmural pressure leading to increased wall stress. Furthermore, a subsequent study by Stone et al [47] showed that pharmacologic lung deflation via decreased airways resistance in patients with hyperinflated COPD improved left and right heart function in addition to pulmonary artery pulsatility. The decompression of the heart and associated pulmonary vasculature lead to normalization of pre-load and improvement in stroke volume. Inflammation may also contribute to poor cardiovascular outcomes in patients with comorbid disease. Specifically, systemic inflammation has been shown to be three-fold higher in COPD without HF [48] and greater than 2-fold higher among patients with HF alone when compared to healthy subjects [49]. Some hypothesize that low grade systemic inflammation in COPD accelerates progression of coronary atherosclerosis, ultimately leading to ischemic cardiomyopathy [50]. More recently, low level systemic inflammation and muscle disuse in the setting of worsening dyspnea has been linked to similar skeletal muscle atrophy in both HD and COPD, which can contribute to morbidity including increasing dyspnea and functional intolerance [51–53].

In this study, we also found that the LVEF was similar between groups with and without emphysema but did not find differences in left ventricular wall thickness or pulmonary artery pressures. However, we did find that LV afterload was markedly elevated among patients with emphysema and HF, which likely contributes to the complex physiologic changes that lead to poor outcomes in this population. There are no data testing the effect of emphysema by CT on LV afterload among patients with HF. Arterial function, as a measure of afterload, is increased in COPD and is associated with the severity of airflow limitation [54,55]. Our study findings add to that data and show an association between emphysema by CT and an increased cardiac afterload specifically among patients with HF. The mechanism by which afterload is increased in patients with emphysema and HF is unclear; however, data suggest that increased transmural pressure due to thoracic pressure swings, extrinsic compression in the setting of hyperinflation, and systemic inflammation may all play a role.

This study has to be interpreted within the study limitations. Specifically, PFTs were not available in all patients. The subset sample size was large enough to appropriately detect a difference in the FEV1/FVC ratio but may not have afforded the power to detect a difference in all pulmonary function measurements between those with and without emphysema on CT scan. Pulmonary function testing is generally considered the gold-standard for the diagnosis of emphysema; however, consistent data have acknowledged difficulty in interpretation of PFT’s among patients with HF. Additionally, as this was a retrospective study, we did no assay serum biomarkers such as NT-proBNP and BNP. These markers have been shown to be elevated in HF and to be strong predictors of adverse outcomes in HF. However, the data in COPD are conflicting; specifically, natriuretic peptide levels have been shown to be a predictor of adverse events in COPD without but not with HF [56–58].

In conclusion, among smokers hospitalized with HF, we found that emphysema on chest CT was highly prevalent and associated with increased afterload and adverse HF events. These data should serve as the basis for further study including considering whether therapy based on the presence of emphysema on CT can improve complex HF outcomes. Specifically, future
studies should consider whether initiation of anti-muscarinics, beta-agonists or inhaled steroids based on the presence of emphysema on chest CT can improve complex HF outcomes.

Supporting information

S1 Table. Individual readmission and mortality data based on emphysema on CT and ejection fraction.

(CSV)

Acknowledgments

Dr. Kohli was supported by NIH/NHLBI 1F32 HL128026-01. Dr. Addison was supported by NIH/NHLBI 5T32HL076136. Dr. Neilan was supported by a kind gift from The Kohlberg Foundation, an American Heart Association Fellow to Faculty Award (12FTF12060588), National Institutes of Health/ National Heart, Lung, and Blood Institute (1R01HL130539-01A1) and National Institutes of Health/ Harvard Center for AIDS Research (P30 AI060354).

Author Contributions

Conceptualization: Puja Kohli, Robert S. Harris, Bartolome R. Celli, Tomas G. Neilan.

Data curation: Puja Kohli, Pedro V. Staziaki, Sumbal A. Janjua, Daniel A. Addison, Travis R. Hallett, Orla Hennessy, Michael T. Lu, Tomas G. Neilan.

Formal analysis: Puja Kohli, Pedro V. Staziaki, Tomas G. Neilan.

Funding acquisition: Puja Kohli, Tomas G. Neilan.

Investigation: Puja Kohli, Sumbal A. Janjua, Richard A. P. Takx, Michael T. Lu, Florian J. Fintelmann, Marc Semigran, Robert S. Harris, Bartolome R. Celli, Tomas G. Neilan.

Methodology: Puja Kohli, Pedro V. Staziaki, Sumbal A. Janjua, Travis R. Hallett, Michael T. Lu, Florian J. Fintelmann, Tomas G. Neilan.

Project administration: Puja Kohli, Pedro V. Staziaki, Tomas G. Neilan.

Resources: Puja Kohli, Michael T. Lu, Florian J. Fintelmann, Robert S. Harris, Udo Hoffmann, Tomas G. Neilan.

Software: Puja Kohli, Michael T. Lu, Florian J. Fintelmann, Udo Hoffmann, Tomas G. Neilan.

Supervision: Puja Kohli, Tomas G. Neilan.

Validation: Puja Kohli, Tomas G. Neilan.

Visualization: Puja Kohli, Tomas G. Neilan.

Writing – original draft: Puja Kohli, Pedro V. Staziaki, Tomas G. Neilan.

Writing – review & editing: Puja Kohli, Pedro V. Staziaki, Richard A. P. Takx, Michael T. Lu, Florian J. Fintelmann, Marc Semigran, Robert S. Harris, Bartolome R. Celli, Udo Hoffmann, Tomas G. Neilan.

References

1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017; 49. https://doi.org/10.1183/13993003.00214–2017
2. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009; 11: 130–139. https://doi.org/10.1093/eurjhf/hfn013 PMID: 19168510

3. Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol. 1987; 17: 207–209. https://doi.org/10.1016/0167-5273(87)90132-X PMID: 3679602

4. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1983; 143: 429–433. PMID: 6830378

5. Merlo M, Pivetta A, Pinamonti B, Stolfo D, Zecchin M, Barbati G, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic diluted cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014; 16: 317–324. https://doi.org/10.1002/ejhf.16 PMID: 24464640

6. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015; 175: 996–1004. https://doi.org/10.1001/jamainternmed.2015.0924 PMID: 25895156

7. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012; 126: 501–506. https://doi.org/10.1161/CIRCULATIONAHA.112.125435 PMID: 22825412

8. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013; 61: 391–403. https://doi.org/10.1016/j.jacc.2012.09.038 PMID: 23219302

9. Spain DM, Siegel H, Bradess VA. Emphysema in apparently healthy adults. Smoking, age, and sex. JAMA. 1973; 242: 322–325. PMID: 4570928

10. Zulueta JJ, Wisnivesky JP, Henschke CI, Yip R, Farooqi AO, McCauley DI, et al. Emphysema scores predict death from COPD and lung cancer. Chest. 2012; 141: 1216–1223. https://doi.org/10.1378/chest.11-0101 PMID: 22016483

11. Klein JS, Gamsu G, Webb WR, Golden JA, Müller NL. High-resolution CT diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity. Radiology. 1992; 182: 817–821. https://doi.org/10.1148/radiology.182.3.1535900 PMID: 15359000

12. Oelsner EC, Hoffman EA, Folsom AR, Carr JJ, Enright PL, Kawut SM, et al. Association of emphysema-like lung on cardiac computed tomography and mortality in persons without airflow obstruction: the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Ann Intern Med. 2014; 161: 863–873. https://doi.org/10.7326/M13-2708 PMID: 25506855

13. Haruna A, Muro S, Nakano Y, Ohara T, Hoshino Y, Ogawa E, et al. CT scan findings of emphysema predict mortality in COPD. Chest. 2010; 138: 635–640. https://doi.org/10.1378/chest.09-2836 PMID: 20382712

14. Smith BM, Kawut SM, Bluemke DA, Basner RC, Gomes AS, Hoffman E, et al. Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. Circulation. 2013; 127: 1503–1511, 1511e1-6. https://doi.org/10.1161/CIRCULATIONAHA.113.001653 PMID: 23493320

15. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010; 362: 217–227. https://doi.org/10.1056/NEJMoa0808836 PMID: 20089972

16. Grau M, Barr RG, Lima JA, Hoffman EA, Bluemke DA, Carr JJ, et al. Percent emphysema and right ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis-Lung and Multi-Ethnic Study of Atherosclerosis-Right Ventricle Studies. Chest. 2013; 144: 136–144. https://doi.org/10.1378/chest.12-1779 PMID: 23450302

17. Beghè B, Verdui A, Bottazzi B, Stendardo M, Fucili A, Balduzzi S, et al. Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study. PloS One. 2013; 8: e80166. https://doi.org/10.1371/journal.pone.0080166 PMID: 24244639

18. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, et al. Unrecognised ventilatory dysfunction in COPD. Eur Respir J. 2012; 39: 51–58. https://doi.org/10.1183/09031936.0044411 PMID: 21700606

19. Straburzyńska-Migaj E, Kauźna-Oleksy M, Maggioni AP, Grajek S, Opolski G, Ponikowski P, et al. Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot)—Polish population. Arch Med Sci AMS. 2015; 11: 743–750. https://doi.org/10.5114/ams.2014.47878 PMID: 26322085

20. Miniati M, Monti S, Botai M, Pavlickova I, Passino C, Emdin M, et al. Prognostic value of alveolar volume in systolic heart failure: a prospective observational study. BMC Pulm Med. 2013; 13: 69. https://doi.org/10.1186/1471-2466-13-69 PMID: 24267007

21. Mentz RJ, FiuzaT M, Wojdyla DM, Chiswell K, Gheorghiade M, Fonarow GC, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive
pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail. 2012; 14: 395–403. https://doi.org/10.1093/eurjhf/hsf009 PMID: 22302663

22. Fisher KA, Stefan MS, Darling C, Lessard D, Goldberg RJ. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. Chest. 2015; 147: 637–645. https://doi.org/10.1378/chest.14-0607 PMID: 25188234

23. Mentz RJ, Felker GM, Ahmad T, Peacock WF, Pitt B, Flizat M, et al. Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J. 2013; 166: 629–635. https://doi.org/10.1016/j.ahj.2013.08.001 PMID: 24093841

24. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: e147–239. https://doi.org/10.1016/j.jacc.2013.05.019 PMID: 23747642

25. National Emphysema Treatment Trial Research Group, Fishman A, Fessler H, Martinez F, McKenna RJ, Naunheim K, et al. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001; 345: 1075–1083. https://doi.org/10.1056/NEJMoa11798 PMID: 11596586

26. Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, et al. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2015; 11: 773–827. https://doi.org/10.5664/jcsm.4858 PMID: 26094920

27. Sacco RL, Kasner SE, Broderick JP, Caplan JJS, Connors JJB, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44: 2064–2089. https://doi.org/10.1161/STR.0b013e3182085836

28. Lang RM, Badano LP, Mor-Avi V, Albiero J, Armstrong A, Emanuele L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003 PMID: 25559473

29. Jong P, Wovinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002; 162: 1689–1694. PMID: 12153731

30. Wang CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, et al. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARMS programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013; 62: 1845–1854. https://doi.org/10.1016/j.jacc.2013.05.072 PMID: 23850914

31. Kaneko H, Suzuki S, Goto M, Arita T, Yузawa Y, Yagi N, et al. Incidence and predictors of rehospitalization of acute heart failure patients. Int Heart J. 2015; 56: 219–225. https://doi.org/10.1536/ihj.14-290 PMID: 25740584

32. Gustafsson F, Schou M, Videbaek L, Dridi N, Ryde H, Handberg J, et al. Incidence and predictors of hospitalization or death in patients managed in multidisciplinary heart failure clinics. Eur J Heart Fail. 2011; 13: 413–419. https://doi.org/10.1093/euhr/jhp025 PMID: 19234309

33. Mangla A, Kane J, Beaty E, Richardson D, Powell LH, Calvin JE. Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol. 2013; 112: 1907–1912. https://doi.org/10.1016/j.amjcard.2013.08.014 PMID: 24063842

34. Felker GM, Leimberger JD, Califf RM, Cuffy MS, Massie BM, Adams KF, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004; 10: 460–466. PMID: 15599835

35. Foraker RE, Rose KM, Suchindran CM, Chang PP, McNell AM, Rosamond WD. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004). Circ Heart Fail. 2011; 4: 308–316. https://doi.org/10.1161/CIRCHEARTFAILURE.110.959031 PMID: 21430286

36. Frigola-Capell E, Comin-Colet J, Davins-Miralles J, Gich-Saladich I, Wensing M, Verdu-Rotellar JM. Trends and predictors of hospitalization, readmissions and length of stay in ambulatory patients with heart failure. Rev Clin Esp. 2013; 213: 1–7. https://doi.org/10.1016/j. jice.2012.10.006 PMID: 23266127

37. Kittleson M, Hurwitz S, Shah MR, Nohria A, Lewis E, Givertz M, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol. 2003; 41: 2029–2035. PMID: 12798577

38. Butler J, Chirovsky D, Phatak H, McNeill A, Cody R. Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail. 2010; 3: 726–745. https://doi.org/10.1161/CIRCHEARTFAILURE.109.920298 PMID: 21081740
41. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piñol MB, Schwartz RS, Asher CR, Navas EV, Totfalusi V, Buitrago I, et al. Predictors of 30-day readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997; 157: 99–104. PMID: 996046

40. Hernandez MB, Schwartz RS, Asher CR, Navas EV, Totfalusi V, Buitrago I, et al. Predictors of 30-day readmission in patients hospitalized with decompressed heart failure. Clin Cardiol. 2013; 36: 542–547. https://doi.org/10.1002/clc.2392763

41. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piñol MB, Schwartz RS, Asher CR, Navas EV, Totfalusi V, Buitrago I, et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Traininging (HF-ACTION). Am Heart J. 2013; 165: 193–199. https://doi.org/10.1016/j.ahj.2012.10.029 PMID: 23351822

42. Rutten FH, Moons KGM, Cramer M-JM, Grobbee DE, Zulthoff NPA, Lammers J-WJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross-sectional diagnostic study. BMJ. 2005; 331: 1379. https://doi.org/10.1136/bmj.38664.661181.55 PMID: 16321994

43. Boussuges A, Pinet C, Molenat F, Burnet H, Ambrosi P, Badier M, et al. Left Atrial and Ventricular Filling In chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2000; 162: 670–675. https://doi.org/10.1164/ajrccm.162.2.9908056 PMID: 1093104

44. Rutten FH, Cramer M-JM, Zulthoff NPA, Lammers J-WJ, Verweij W, Grobbee DE, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007; 9: 651–659. https://doi.org/10.1016/j.ejheart.2007.01.010 PMID: 17347037

45. Magee MJ, Herbert MA, Roper KL, Holper E, Dewey TM, Snelus T, et al. Pulmonary function tests over-estimate chronic pulmonary disease in patients with severe aortic stenosis. Ann Thorac Surg. 2013; 96: 1329–1335. https://doi.org/10.1016/j.athoracsur.2013.04.123 PMID: 23891405

46. Alter P, van de Sand K, Nell C, Figiel JH, Greulich T, Vogelmeier CF, et al. Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure. Respir Res. 2015; 109: 1131–1137. https://doi.org/10.1186/s12890-015-0056-7 PMID: 26231928

47. Stone IS, Barnes NC, James W-Y, Midwinter D, Boubertak R, Follows R, et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2016; 193: 717–726. https://doi.org/10.1164/rccm.201508-1647OC PMID: 26550687

48. Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008; 63: 306–311. https://doi.org/10.1136/thx.2007.083493 PMID: 18024535

49. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated Circulating Levels of Tumor Necrosis Factor alpha IL-6 and -8 in Severe Chronic Heart Failure. N Engl J Med. 1990; 323: 236–241. https://doi.org/10.1056/NEJM199007263230405 PMID: 2195340

50. Steele P, Ellis JH, Dyke DV, Sutton F, Creagh E, Davies H. Left ventricular ejection fraction in severe chronic obstructive airways disease. Am J Med. 1975; 59: 21–28. https://doi.org/10.1016/0002-9343(75)90317-4 PMID: 12740256

51. Casabur R, Gosselink R, Decramer M, Dekhuijzen RPN, Fournier M, Lewis MI, et al. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 101: 159.

52. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM, Fournier M, Lewis MI, et al. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr. 2000; 71: 1033–1047. https://doi.org/10.1093/ajcn/71.5.1033 PMID: 10799364

53. Gosker HR, Lencer NHMK, Franssen FME, van der Vusse GJ, Wouters EFM, Schols AMWJ. Striking Similarities in Systemic Factors Contributing to Decreased Exercise Capacity in Patients With Severe Chronic Heart Failure or COPD. Chest. 2003; 123: 1416–1424. https://doi.org/10.1378/chest.123.5.1416 PMID: 12740256

54. Zureik M, Benetos A, Neukirch C, Courbon D, Bean K, Thomas F, et al. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med. 2001; 164: 2181–2185. https://doi.org/10.1164/ajrccm.164.12.2107137 PMID: 11751184

55. Sabit R, Bolton CE, Edwards PH, Petit RJ, Evans WD, McEniery CM, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175: 1259–1265. https://doi.org/10.1164/rccm.200701-067OC PMID: 17363772

56. Papaioanou AI, Mazioti A, Kiroopoulos T, Tsiioni I, Koutsokera A, Tanou K, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med. 2010; 104: 275–282. https://doi.org/10.1016/j.resmed.2009.09.016 PMID: 19854037
57. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med Tokyo Jpn. 2009; 48: 503–512.

58. Høiseth AD, Omland T, Hagve T-A, Brekke PH, Søyseth V. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD—a prospective cohort study. Respir Res. 2012; 13: 97. https://doi.org/10.1186/1465-9921-13-97 PMID: 23107284